Navigation Links
Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
Date:10/10/2007

RADNOR, Pa., and BALTIMORE, Oct. 10 /PRNewswire/ -- The following statement was issued jointly today by the law firms of Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC:

SCHIFFRIN BARROWAY TOPAZ & KESSLER, LLP and JANET JENNER & SUGGS, LLC comment on the October 9, 2007 announcement by ConAgra Foods that it is suspending production of its pot pies while federal investigators inspect the company for the source of a Salmonella outbreak that has injured over 100 people in dozens of states. The company has issued an "advisory" to consumers to not eat or use frozen chicken or turkey pot pie products with "P-9" printed on the side of packaging.

The U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) is investigating ConAgra due to reported illnesses linked to their products. Banquet brand and generic store brand frozen not-ready-to-eat pot pie products with "P-9" printed on the side of the package may be the potential source of reported illnesses caused by Salmonella based on epidemiological evidence collected by the Centers for Disease Control and Prevention (CDC) and State public health departments. On Monday, the CDC sent inspectors into ConAgra's pot pie plant. The CDC, which is leading the investigation, said 30 states have reported 139 cases of Salmonella poisoning, including 23 that required hospitalization. Wisconsin had the most cases (19), followed by Pennsylvania (13).

"Just seven months after ConAgra's recall of peanut butter due to Salmonella problems, we learn of yet another ConAgra food safety problem. We will aggressively investigate to determine if there is evidence of a pattern of neglect. Instead of blaming consumers for improper cooking, ConAgra needs to clean up its own act and ensure the safety of its food. Stop passing the buck. ConAgra must be held accountable." said Tobias L. Millrood, partner with Schiffrin Barroway Topaz & Kessler, LLP

According to the U.S. Department of
'/>"/>

SOURCE Schiffrin Barroway Topaz & Kessler, LLP; Janet Jenner &Suggs, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
2. FDA Announces Change of Location Notice for Upcoming Advisory Committee Meeting
3. Media Advisory: ACC Updated Schedule
4. Nektar Threraputics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference
5. Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be Presented at American Thoracic Society International Conference
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Fragile X, Down Syndromes Linked to Faulty Brain Communication, Stanford Researcher Finds
8. Diabetes Linked to Higher Parkinsons Risk
9. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4Commercial Insurance Buyers Benefit From Ample Capacity 14306 1Commercial Insurance Buyers Benefit From Ample Capacity 14306 2Commercial Insurance Buyers Benefit From Ample Capacity 14306 3UAB professors book promises solution for teaching evolution without conflict 10199 1UAB professors book promises solution for teaching evolution without conflict 10199 2A New Jersey Anti Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson NJ Small Businesses 58591 1A New Jersey Anti Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson NJ Small Businesses 58591 2A New Jersey Anti Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson NJ Small Businesses 58591 3A New Jersey Anti Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson NJ Small Businesses 58591 4
Breaking Medicine News(10 mins):Health News:Talyst and MultiCare Partner to Improve Patient Safety 2Health News:Talyst and MultiCare Partner to Improve Patient Safety 3Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 2Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 3Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 4Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 5Health News:The Breema Center Presents a Yearlong Campaign to Transform Stress into Harmony in 2010 and Beyond 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 2Health News:Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions 3Health News:Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential 2